SCHEMBL985510

SCHEMBL985510

NNC(=Nc1cccc(F)c1F)c1cccnc1N

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
REV1 Q9UBZ9 1/20 0.39
NAPRT Q6XQN6 1/20 0.39
PRKCI P41743 2/20 0.36
MAPT P10636 1/20 0.33
HTT P42858 1/20 0.33
P2RX7 Q99572 1/20 0.33
CES2 O00748 1/20 0.32
BCHE P06276 1/20 0.32
CES1 P23141 1/20 0.32
NPC1 O15118 1/20 0.32
PKM P14618 1/20 0.32
AGTR1 P30556 1/20 0.32
RAB9A P51151 1/20 0.32
IDO1 P14902 1/20 0.31
CDK5 Q00535 1/20 0.31
CDK5R1 Q15078 1/20 0.31
KDM4E B2RXH2 2/20 0.30
MEN1 O00255 1/20 0.30
USP2 O75604 1/20 0.30
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL982684 0.87 NAPRT (0.37) NAPRTPRKCIP2RX7IDO1ALDH1A1
SCHEMBL4831458 0.79 MAP2K1 (0.42) CDK5CDK5R1KMT2A
SCHEMBL982426 0.79 S100B (0.41) NAPRTPRKCIP2RX7IDO1KDM4E
SCHEMBL985507 0.74 PRKCI (0.39) NAPRTPRKCIMAPTHTTKDM4E
SCHEMBL985508 0.74 PRKCI (0.39) NAPRTPRKCIMAPTHTTKDM4E
SCHEMBL14399255 0.71 TP53 (0.37) NAPRTPRKCIMAPTHTTP2RX7
SCHEMBL985872 0.68 PRKCI (0.57) NAPRTPRKCIMAPTHTTNPC1
SCHEMBL15061504 0.67 REV1 (0.38) REV1CES2BCHECES1ALDH1A1
SCHEMBL11946796 0.64 PABPC1 (0.40) NAPRTPRKCIMAPTHTTMEN1
SCHEMBL982681 0.64 PABPC1 (0.40) NAPRTPRKCIMAPTHTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232406-B2 c-MET protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-31 US disclosed
US-7872031-B2 c-MET protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-01-18 US disclosed
EP-2004625-B1 C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS VERTEX PHARMA (US) 2009-12-30 EP disclosed
US-20070254868-A1 C-MET protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254868-A1 C-MET protein kinase inhibitors MET, PRKCH, ABL1 REV1 1933/4885NAPRT 4625/4885PRKCI 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.